LumiraDx SARS-CoV-2 Antibody Test Demonstrates High Sensitivity and Specificity in Point of Care Testing for COVID-19
LumiraDx SARS-CoV-2 Antigen Test Demonstrates High Sensitivity in Point of Care Testing for COVID-19
Performance evaluation of a rapid point-of-care microfluidic immunofluorescence assay for the detection of SARS-CoV-2 antibodies
The LumiraDx SARS-CoV-2 Antigen Test aligns with detection of infectious samples from immunocompetent individuals with none to mild and moderate symptoms
Summary of the Evaluation of 32 rapid tests for detection of IgG antibodies against SARS-CoV-2 (NOKLUS)
Establishing an Anticoagulation “Drive Through” Clinic during the COVID-19 Pandemic using the LumiraDx Platform INR Test
An evaluation of the detection of SARS-CoV-2 antigen in a cohort of symptomatic and asymptomatic patients: Report from the evaluation of SKUP
Performance evaluation of the LumiraDx SARS-CoV-2 Antigen Test to aid diagnosis of acute COVID-19 at the point of care
Evaluation of the Accuracy of the LumiraDx INR Test Using Patients in Receipt of Phenprocoumon Anticoagulation Therapy
Evaluation of the Accuracy of INR values measured by a POCT system in a German Clinic with patients taking Phenprocoumon as VKA Therapy.
Laboratory accuracy assessment of a novel INR Point of Care Test compared with laboratory reference methods used across four independent clinical sites.
Product Evaluation of the LumiraDx Platform and INR Test at the medical practice Dres. Schreiber, Steinbauer & Dechant
Performance of the LumiraDx Platform INR Test in a point of care setting compared to an established laboratory reference method